Nautilus Biotech Q1 net loss $15M, cash $302M; platform launch mid-2024

Nautilus Biotechnology, Inc.

2023-Q1 EPS reported -$0.12

Net loss $15.0M vs $15.8M year ago; operating expenses $18.1M, up 13% YoY on higher headcount.
Cash, equivalents and investments $302.0M as of March 31, 2023; runway expected into 2025.
Platform (instruments, reagents, software) launch planned for mid-2024.
Granted 4 new US patents in Q1, raising total to 12 granted patents.
Announced three winners of First Access Challenge for Early Access Program.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Nautilus Biotechnology, Inc. reported first quarter ended March 31, 2023 results: net income Net loss was $15.0 million.

Period: first quarter ended March 31, 2023
Net income: Net loss was $15.0 million
Result: reported results

Exact text from the filing

Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Nautilus Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001808805-23-000045

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.